# BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.

> **NCT06598722** · PHASE2 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 206 (estimated)

## Conditions studied

- Lymphoblastic Lymphoma, Adult
- Lymphoblastic Leukemia, Acute T-cell

## Interventions

- **DRUG:** BCL-2 inhibitors combined with the HyperCVAD regimen
- **OTHER:** Propensity score matching historical data

## Key facts

- **NCT ID:** NCT06598722
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-07
- **Primary completion:** 2026-08-07
- **Final completion:** 2027-08-07
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598722, "BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06598722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*